Recently, emerging strategies against liver fibrosis have been proposed, such as selective antagonization of CB1 cannabinoid receptor [2], targeting 5-hydroxytryptamine (5-HT) class of receptors [3], inhibition of Toll-like receptor 4 (TLR4) [4], and activation of STAT1 [5], etc. However, the efficient strategies are still lacking due to the complicated pathogenesis associated with this disease [6]. Here, TLR4 is linked to Hepatic fibrosis.